Motilal Oswal maintains buy on Torrent Pharma
Outperformance has been led by strong growth in exports. Stock trades at 15-times FY15 earnings per share and 13-times FY16 EPS. Net profit growth is faster than ebitda mainly due to lower than expected tax expenses. Growth in domestic formulations business was in-line. Target Rs 555.